Cargando…

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease

INTRODUCTION: Alzheimer's disease (AD) is associated with synapse loss. Souvenaid, containing the specific nutrient combination Fortasyn Connect, was designed to improve synapse formation and function. The NL-ENIGMA study explored the effect of Souvenaid on synapse function in early AD by asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheltens, Nienke M.E., Briels, Casper T., Yaqub, Maqsood, Barkhof, Frederik, Boellaard, Ronald, van der Flier, Wiesje M., Schwarte, Lothar A., Teunissen, Charlotte E., Attali, Amos, Broersen, Laus M., van Berckel, Bart N.M., Scheltens, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804721/ https://www.ncbi.nlm.nih.gov/pubmed/31650005 http://dx.doi.org/10.1016/j.trci.2019.08.002

Ejemplares similares

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2018)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer’s disease
por: Tolboom, Nelleke, et al.
Publicado: (2009)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Circulating metabolites are associated with brain atrophy and white matter hyperintensities
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness
por: Dubbelman, Mark A., et al.
Publicado: (2022)

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
por: Rijpma, Anne, et al.
Publicado: (2015)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study
por: de Waal, Hanneke, et al.
Publicado: (2014)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
por: Ebenau, Jarith L., et al.
Publicado: (2021)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Evaluation of Tracer Kinetic Models for Analysis of [(18)F]FDDNP Studies
por: Yaqub, Maqsood, et al.
Publicado: (2009)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Reproducibility of quantitative (R)-[(11)C]verapamil studies
por: van Assema, Daniëlle ME, et al.
Publicado: (2012)

Multitracer model for staging cortical amyloid deposition using PET imaging
por: Collij, Lyduine E., et al.
Publicado: (2020)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kr6q3h6tkabmt67asdqt2dv8mt